

Ayalew Tefferi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9386227/ayalew-tefferi-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

815 papers	43,364 citations	107 h-index	191 g-index
841 ext. papers	49,740 ext. citations	5.6 avg, IF	7.91 L-index

#	Paper	IF	Citations
815	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.. <i>Blood Cancer Journal</i> , 2022 , 12, 12	7	
814	A Population-Based Study of Acute Panmyelosis with Myelofibrosis in the United States: 2004-2015.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
813	Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.. <i>American Journal of Hematology</i> , 2022 ,	7.1	4
812	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.. <i>Blood Cancer Journal</i> , 2022 , 12, 7	7	1
811	Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
810	Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
809	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. <i>Blood Cancer Journal</i> , 2022 , 12, 26	7	1
808	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. <i>Haematologica</i> , 2022 ,	6.6	1
807	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.. <i>Blood Cancer Journal</i> , 2022 , 12, 28	7	2
806	Erythrocytosis associated with (), (), or mutations: The Mayo Clinic experience.. <i>Haematologica</i> , 2022 ,	6.6	1
805	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.. <i>Leukemia Research</i> , 2022 , 106818	2.7	0
804	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.. <i>American Journal of Hematology</i> , 2022 ,	7.1	2
803	Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.. <i>American Journal of Hematology</i> , 2022 ,	7.1	3
802	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
801	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.. <i>Blood Cancer Journal</i> , 2022 , 12, 44	7	1
800	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
799	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".. <i>Blood Cancer Journal</i> , 2022 , 12, 55	7	1

798	Myeloproliferative neoplasms - a global view.. <i>British Journal of Haematology</i> , 2022 ,	4.5	1
797	Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy.. <i>American Journal of Ophthalmology Case Reports</i> , 2022 , 26, 101554	1.3	0
796	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. <i>American Journal of Hematology</i> , 2021 ,	7.1	2
795	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.. <i>Blood Cancer Journal</i> , 2021 , 11, 199	7	6
794	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , 2021 ,	4.5	3
793	High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. <i>Blood</i> , 2021 , 138, 1492-1492	2.2	
792	Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera. <i>Blood</i> , 2021 , 138, 1499-1499	2.2	1
791	A JAK2V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis. <i>Blood</i> , 2021 , 138, 237-237	2.2	2
790	Cerebral Venous Thrombosis and Myeloproliferative Neoplasms: A Three-Center Study of 74 Consecutive Cases. <i>Blood</i> , 2021 , 138, 1493-1493	2.2	1
789	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021 , 138, 1267-1267	2.2	
788	Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases. <i>Blood</i> , 2021 , 138, 3629-3629	2.2	
787	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2021 , 138, 2592-2592	2.2	
786	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. <i>Blood</i> , 2021 , 138, 219-219	2.2	2
785	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2021 , 138, 3684-3684	2.2	
784	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. <i>Blood</i> , 2021 , 138, 238-238	2.2	0
783	Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2021 , 138, 3651-3651	2.2	1
782	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2021 , 138, 1470-1470	2.2	
781	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. <i>Blood</i> , 2021 , 138, 3657-3657	2.2	0

780	A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis. <i>Blood</i> , 2021 , 138, 1498-1498	2.2	0
779	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). <i>Blood</i> , 2021 , 138, 1096-1096	2.2	
778	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021 , 138, 3368-3368	2.2	0
777	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2021 , 97, E62	7.1	0
776	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. <i>Blood</i> , 2021 , 138, 3691-3691	2.2	0
775	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. <i>Blood</i> , 2021 , 138, 3377-3377	2.2	
774	The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events. <i>Blood</i> , 2021 , 138, 3630-3630	2.2	
773	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2021 , 97, E35	7.1	2
772	A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. <i>American Journal of Hematology</i> , 2021 , 96, E464-E468	7.1	0
771	High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. <i>American Journal of Hematology</i> , 2021 , 96, 1647-1654	7.1	3
770	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA + venetoclax chemotherapy. <i>American Journal of Hematology</i> , 2021 , 96, E108-E111	7.1	3
769	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. <i>Blood Cancer Journal</i> , 2021 , 11, 43	7	3
768	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 46	7	1
767	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 54	7	1
766	Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. <i>American Journal of Hematology</i> , 2021 , 96, E182-E184	7.1	6
765	Mutations and thrombosis in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2021 , 11, 77	7	8
764	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. <i>Blood Advances</i> , 2021 , 5, 2272-2278	7.8	3
763	JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. <i>Leukemia</i> , 2021 , 35, 2166-2181	10.7	7

762	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 781-789	7.1	17
761	New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat. <i>American Journal of Hematology</i> , 2021 , 96, 761-763	7.1	2
760	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. <i>Blood Cancer Journal</i> , 2021 , 11, 122	7	0
759	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021 , 96, E327-E330	7.1	2
758	Development and application of novel immunoassays for eosinophil granule major basic proteins to evaluate eosinophilia and myeloproliferative disorders. <i>Journal of Immunological Methods</i> , 2021 , 493, 113015	2.5	0
757	Current Management of Chronic Neutrophilic Leukemia. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 59	5.4	0
756	Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. <i>British Journal of Haematology</i> , 2021 , 195, 133-137	4.5	1
755	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. <i>British Journal of Haematology</i> , 2021 , 195, 244-248	4.5	7
754	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. <i>Leukemia</i> , 2021 , 35, 644-649	10.7	6
753	Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2021 , 96, 145-162	7.1	46
752	Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. <i>American Journal of Hematology</i> , 2021 , 96, 354-366	7.1	4
751	Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". <i>American Journal of Hematology</i> , 2021 , 96, 379-394	7.1	8
750	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 1-9	2.6	2
749	Young platelet millionaires with essential thrombocythemia. <i>American Journal of Hematology</i> , 2021 , 96, E93-E95	7.1	5
748	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021 , 11, 49	7	11
747	Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms. <i>American Journal of Hematology</i> , 2021 , 96, E392-E396	7.1	2
746	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021 , 195, 413-416	4.5	1
745	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021 , 96, 1450-1460	7.1	1

744	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. <i>American Journal of Hematology</i> , 2021 , 96, 1472-1480	7.1	2
743	Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. <i>Leukemia</i> , 2021 , 35, 3339-3351	10.7	7
742	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E433-E436	7.1	2
741	Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 1580-1586	7.1	2
740	MPN-377: Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, S338-S339	2	2
739	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020 , 10, 68	7	7
738	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020 , 10, 36	7	6
737	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>British Journal of Haematology</i> , 2020 , 189, e104-e108	4.5	4
736	Myelofibrosis biology and contemporary management. <i>British Journal of Haematology</i> , 2020 , 191, 152-170	10.5	21
735	Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies. <i>American Journal of Hematology</i> , 2020 , 95, 1224	7.1	3
734	A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020 , 95, E257	7.1	2
733	Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. <i>British Journal of Haematology</i> , 2020 , 190, e316-e320	4.5	4
732	The new WHO classification for essential thrombocythemia calls for revision of available evidences. <i>Blood Cancer Journal</i> , 2020 , 10, 22	7	6
731	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. <i>Leukemia</i> , 2020 , 34, 2519-2524	10.7	10
730	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. <i>British Journal of Haematology</i> , 2020 , 189, 291-302	4.5	58
729	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. <i>American Journal of Hematology</i> , 2020 , 95, E86-E89	7.1	2
728	Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. <i>American Journal of Hematology</i> , 2020 , 95, E114-E117	7.1	6
727	Special considerations in the management of patients with myelodysplastic syndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. <i>American Journal of Hematology</i> , 2020 , 95, E203-E208	7.1	7

726	WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic. <i>American Journal of Hematology</i> , 2020 , 95, E172-E174	7.1	12
725	A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015. <i>Blood</i> , 2020 , 136, 48-48	2.2	
724	Efficacy of Venetoclax Plus Hypomethylating Agent in Blast Phase Myeloproliferative Neoplasm. <i>Blood</i> , 2020 , 136, 21-21	2.2	1
723	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. <i>Blood</i> , 2020 , 136, 44-44	2.2	
722	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. <i>Blood</i> , 2020 , 136, 43-44	2.2	
721	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020 , 136, 35-36	2.2	
720	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , 2020 , 136, 30-31	2.2	
719	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2020 , 136, 19-20	2.2	
718	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. <i>Blood</i> , 2020 , 136, 39-40	2.2	6
717	Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms. <i>Blood</i> , 2020 , 136, 1-1	2.2	2
716	Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. <i>Blood</i> , 2020 , 136, 909-913	2.2	28
715	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. <i>Blood Advances</i> , 2020 , 4, 5716-5721	7.8	5
714	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. <i>American Journal of Hematology</i> , 2020 , 95, E31-E34	7.1	1
713	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020 , 95, 156-166	7.1	27
712	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020 , 95, E68-E72	7.1	2
711	Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2020 , 95, 97-115	7.1	54
710	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. <i>Leukemia</i> , 2020 , 34, 1407-1421	10.7	40
709	Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management. <i>American Journal of Hematology</i> , 2020 , 95, 212-224	7.1	12

708	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020 , 10, 100	7	3
707	Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. <i>Blood Cancer Journal</i> , 2020 , 10, 122	7	8
706	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020 , 10, 121	7	7
705	Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2020 , 95, 1599-1613	7.1	64
704	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020 , 95, 1511-1521	7.1	28
703	Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. <i>British Journal of Haematology</i> , 2020 , 191, e120-e124	4.5	13
702	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. <i>Blood Advances</i> , 2020 , 4, 3677-3687	7.8	17
701	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. <i>Modern Pathology</i> , 2020 , 33, 334-343	9.8	6
700	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. <i>Blood Cancer Journal</i> , 2019 , 9, 12	7	28
699	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>American Journal of Hematology</i> , 2019 , 94, E231-E234	7.1	4
698	Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 4898-4906	12.9	42
697	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. <i>Leukemia</i> , 2019 , 33, 2522-2553	10.7	1
696	World Health Organization class-independent risk categorization in mastocytosis. <i>Blood Cancer Journal</i> , 2019 , 9, 29	7	5
695	Comments on pre-fibrotic myelofibrosis and how should it be managed. <i>British Journal of Haematology</i> , 2019 , 186, 358-360	4.5	2
694	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 599-610	6.4	50
693	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. <i>American Journal of Hematology</i> , 2019 , 94, 767-779	7.1	27
692	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. <i>Blood Cancer Journal</i> , 2019 , 9, 11	7	8
691	AKT activation is a feature of CALR mutant myeloproliferative neoplasms. <i>Leukemia</i> , 2019 , 33, 271-274	10.7	3

690	Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2019 , 9, 65	7	12
689	Etiologies of Extreme Thrombocytosis: A Contemporary Series. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1542-1550	5	5
688	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1467-1474	6.4	8
687	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 3003-3003	2.2	1
686	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2019 , 134, 558-558	2.2	17
685	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019 , 134, 4182-4182	2.2	1
684	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019 , 134, 3005-3005	2.2	
683	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019 , 134, 5441-5441	2.2	
682	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 1697-1697	2.2	
681	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019 , 134, 3863-3863	2.2	
680	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019 , 134, 1710-1710	2.2	
679	Essential Thrombocythemia. <i>New England Journal of Medicine</i> , 2019 , 381, 2135-2144	59.2	50
678	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. <i>Leukemia Research</i> , 2019 , 87, 106264	2.7	
677	Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Hematological Oncology</i> , 2019 , 37, 96-102	1.3	7
676	Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2019 , 94, 133-143	7.1	119
675	Mutations and prognosis in myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1112-1113.	9	1
674	Calculator-free point-of-care prognostication in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2019 , 94, E99-E101	7.1	
673	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the V617F mutation. <i>Haematologica</i> , 2019 , 104, e236-e239	6.6	13

672	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". <i>American Journal of Hematology</i> , 2019 , 94, 475-488	7.1	23
671	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. <i>Leukemia</i> , 2019 , 33, 780-785	10.7	2
670	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2019 , 94, 299-305	7.1	5
669	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. <i>American Journal of Hematology</i> , 2019 , 94, 286-290	7.1	3
668	Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis. <i>American Journal of Hematology</i> , 2019 , 94, E1-E2	7.1	10
667	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , 2019 , 94, 5-9	7.1	3
666	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, E144-E146	7.1	
665	Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. <i>American Journal of Hematology</i> , 2018 , 93, 578-587	7.1	19
664	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. <i>Leukemia</i> , 2018 , 32, 2274-2278	10.7	47
663	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. <i>American Journal of Hematology</i> , 2018 , 93, E146-E148	7.1	7
662	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018 , 32, 1057-1069	10.7	263
661	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, E164-E167	7.1	1
660	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia</i> , 2018 , 32, 1631-1642	10.7	117
659	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. <i>Leukemia</i> , 2018 , 32, 1254-1258	10.7	26
658	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018 , 32, 1200-1210	10.7	68
657	Chronic neutrophilic leukemia: new science and new diagnostic criteria. <i>Blood Cancer Journal</i> , 2018 , 8, 19	7	11
656	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018 , 8, 18	7	13
655	FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1520-1522	1.9	5

654	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, 649-654	7.1	26
653	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. <i>Leukemia</i> , 2018 , 32, 1189-1199	10.7	65
652	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. <i>American Journal of Hematology</i> , 2018 , 93, 691-697	7.1	34
651	Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. <i>American Journal of Hematology</i> , 2018 , 93, E123-E125	7.1	30
650	Mayo CALR mutation type classification guide using alpha helix propensity. <i>American Journal of Hematology</i> , 2018 , 93, E128-E129	7.1	11
649	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. <i>Blood Cancer Journal</i> , 2018 , 8, 15	7	221
648	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. <i>Blood Cancer Journal</i> , 2018 , 8, 8	7	0
647	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. <i>Blood Cancer Journal</i> , 2018 , 8, 12	7	30
646	JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. <i>American Journal of Hematology</i> , 2018 , 93, E93-E96	7.1	14
645	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. <i>Leukemia</i> , 2018 , 32, 1035-1038	10.7	35
644	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 835-838	4.5	23
643	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, E103-E107	7.1	
642	Essential thrombocythemia treatment algorithm 2018. <i>Blood Cancer Journal</i> , 2018 , 8, 2	7	60
641	Polycythemia vera treatment algorithm 2018. <i>Blood Cancer Journal</i> , 2018 , 8, 3	7	43
640	Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. <i>British Journal of Haematology</i> , 2018 , 182, 437-440	4.5	14
639	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. <i>Leukemia</i> , 2018 , 32, 1850-1856	10.7	19
638	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2998-3001	1.9	5
637	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018 , 8, 32	7	9

636	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018 , 8, 29	7	27
635	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. <i>British Journal of Haematology</i> , 2018 , 182, 141-145	4.5	2
634	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. <i>British Journal of Haematology</i> , 2018 , 182, 594-597	4.5	18
633	Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>American Journal of Hematology</i> , 2018 , 93, E27-E30	7.1	14
632	Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. <i>Leukemia</i> , 2018 , 32, 837-839	10.7	20
631	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. <i>American Journal of Hematology</i> , 2018 , 93, 65-73	7.1	37
630	Revisiting the need for bone marrow examination in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, 5-7	7.1	1
629	Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018 , 8, 57	7	17
628	Myelofibrosis Treatment Algorithm 2018. <i>Blood Cancer Journal</i> , 2018 , 8, 72	7	22
627	Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2018 , 93, 1551-1560	7.1	85
626	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1117-e1122	3.3	1
625	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, E235-E238	7.1	7
624	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. <i>Blood Cancer Journal</i> , 2018 , 8, 21	7	17
623	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. <i>Leukemia</i> , 2018 , 32, 2512-2518	10.7	19
622	Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. <i>Blood Advances</i> , 2018 , 2, 1980-1984	7.8	8
621	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. <i>American Journal of Hematology</i> , 2018 , 93, 1461-1466	7.1	17
620	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. <i>American Journal of Hematology</i> , 2018 , 93, 1347-1357	7.1	7
619	Blast-phase chronic myelomonocytic leukemia: more than just semantics. <i>Leukemia</i> , 2018 , 32, 2093-2094	10.7	1

618	How I treat myelofibrosis after failure of JAK inhibitors. <i>Blood</i> , 2018 , 132, 492-500	2.2	30
617	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1363-1374	6.4	14
616	Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia. <i>Hematological Oncology</i> , 2018 , 36, 718-720	1.3	7
615	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). <i>Blood</i> , 2018 , 132, 578-578	2.2	5
614	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. <i>Blood</i> , 2018 , 132, 4301-4301	2.2	0
613	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018 , 132, 3035-3035	2.2	1
612	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. <i>Blood</i> , 2018 , 132, 3040-3040	2.2	1
611	Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis. <i>Blood</i> , 2018 , 132, 688-688	2.2	7
610	Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study. <i>Blood</i> , 2018 , 132, 5067-5067	2.2	2
609	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2018 , 132, 1773-1773	2.2	3
608	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2018 , 132, 1821-1821	2.2	9
607	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. <i>Blood</i> , 2018 , 132, 3037-3037 ²		
606	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. <i>Blood</i> , 2018 , 132, 4300-4300	2.2	
605	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018 , 132, 2722-2722	2.2	2
604	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. <i>Blood</i> , 2018 , 132, 3034-3034	2.2	
603	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. <i>Blood</i> , 2018 , 132, 1761-1761	2.2	
602	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. <i>Blood</i> , 2018 , 132, 4287-4287	2.2	
601	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. <i>Blood</i> , 2018 , 132, 582-582	2.2	

600	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. <i>Blood</i> , 2018 , 132, 1767-1767	2.2	
599	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018 , 132, 4344-4344	2.2	
598	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. <i>Blood</i> , 2018 , 132, 3050-3050	2.2	
597	Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients. <i>Blood</i> , 2018 , 132, 5457-5457	2.2	
596	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. <i>Blood</i> , 2018 , 132, 3033-3033	2.2	
595	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. <i>Blood</i> , 2018 , 132, 4291-4291	2.2	
594	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. <i>Blood</i> , 2018 , 132, 3036-3036	2.2	
593	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. <i>Blood</i> , 2018 , 132, 3100-3100	2.2	
592	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2689-2689	2.2	
591	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018 , 132, 3044-3044	2.2	
590	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. <i>Blood</i> , 2018 , 132, 1771-1771	2.2	
589	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. <i>American Journal of Hematology</i> , 2018 , 93, 348-355	7.1	54
588	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 678-681	4.5	10
587	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. <i>American Journal of Hematology</i> , 2018 , 93, E61-E64	7.1	23
586	Polycythemia vera and essential thrombocythemia: algorithmic approach. <i>Current Opinion in Hematology</i> , 2018 , 25, 112-119	3.3	8
585	Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. <i>American Journal of Hematology</i> , 2018 , 93, E47-E49	7.1	35
584	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018 , 36, 310-318	2.2	224
583	MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1769-1770	2.2	123

582	MPL-mutated essential thrombocythemia: a morphologic reappraisal. <i>Blood Cancer Journal</i> , 2018 , 8, 1217		13
581	Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients. <i>Blood Cancer Journal</i> , 2018 , 8, 119	7	23
580	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. <i>Blood Cancer Journal</i> , 2018 , 8, 118	7	3
579	Genetic predictors of response to specific drugs in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018 , 8, 120	7	0
578	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <i>American Journal of Hematology</i> , 2018 , 93, E401-E404	7.1	2
577	Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFR β Mutation. <i>Acta Haematologica</i> , 2018 , 140, 67-70	2.7	0
576	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018 , 8, 82	7	14
575	Mutations and karyotype predict treatment response in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, 1420-1426	7.1	18
574	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. <i>American Journal of Hematology</i> , 2018 , 93, E383-E386	7.1	2
573	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <i>American Journal of Hematology</i> , 2018 , 93, 1474-1484	7.1	31
572	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. <i>Blood Advances</i> , 2018 , 2, 370-380	7.8	55
571	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. <i>Blood Advances</i> , 2018 , 2, 2964-2972	7.8	40
570	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2018 , 93, 824-840	7.1	73
569	Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience. <i>American Journal of Hematology</i> , 2018 , 93, 1029	7.1	26
568	The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. <i>American Journal of Hematology</i> , 2017 , 92, 454-459	7.1	9
567	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2017 , 92, 297-310	7.1	39
566	Diagnostic impact of the 2016 revised who criteria for polycythemia vera. <i>American Journal of Hematology</i> , 2017 , 92, 417-419	7.1	18
565	Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. <i>Blood Cancer Journal</i> , 2017 , 7, e538	7	16

564	The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. <i>British Journal of Haematology</i> , 2017 , 178, 57-60	4.5	2
563	Liver function test abnormalities and their clinical relevance in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2017 , 7, e557	7	1
562	Cardiac tamponade in myelofibrosis: A Mayo clinic series of nine consecutive cases. <i>American Journal of Hematology</i> , 2017 , 92, E544-E545	7.1	2
561	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. <i>Blood Cancer Journal</i> , 2017 , 7, e550	7	14
560	Monocytosis in polycythemia vera: Clinical and molecular correlates. <i>American Journal of Hematology</i> , 2017 , 92, 640-645	7.1	31
559	Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2017 , 99, 36-41	3.8	2
558	Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 542-548	7.1	41
557	Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2017 , 92, 94-108	7.1	129
556	Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. <i>Leukemia</i> , 2017 , 31, 2851-2852	10.7	16
555	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. <i>American Journal of Hematology</i> , 2017 , 92, 1311-1317	7.1	50
554	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. <i>Blood Cancer Journal</i> , 2017 , 7, e584	7	49
553	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017 , 92, E626-E627	7.1	1
552	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. <i>American Journal of Hematology</i> , 2017 , 92, E614-E618	7.1	20
551	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. <i>American Journal of Hematology</i> , 2017 , 92, 1187-1192	7.1	17
550	Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. <i>American Journal of Hematology</i> , 2017 , 92, 1193-1197	7.1	18
549	Genetic Risk Assessment in Myeloproliferative Neoplasms. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 1283-1290	6.4	34
548	Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 1118-1128	6.4	57
547	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 56-61	7.1	48

546	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1488-1493	1.9	35
545	A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. <i>Leukemia</i> , 2017 , 31, 896-902	10.7	35
544	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. <i>Leukemia and Lymphoma</i> , 2017 , 58, 872-881	1.9	18
543	Acute leukemia in pregnancy: a single institution experience with 23 patients. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1052-1060	1.9	9
542	The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. <i>American Journal of Hematology</i> , 2017 , 92, E5-E6	7.1	32
541	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. <i>Blood Cancer Journal</i> , 2017 , 7, 657	7	5
540	Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. <i>Blood Cancer Journal</i> , 2017 , 7, 662	7	55
539	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). <i>Blood Cancer Journal</i> , 2017 , 7, 658	7	13
538	Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. <i>Journal of Clinical Investigation</i> , 2017 , 127, 1316-1320	15.9	47
537	Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. <i>Leukemia</i> , 2016 , 30, 889-96	10.7	76
536	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. <i>Blood Advances</i> , 2016 , 1, 21-30	7.8	163
535	Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review. <i>Journal of Oncology Practice</i> , 2016 , 12, 611-21	3.1	15
534	MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2016 , 6, e487	7	19
533	Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2016 , 91, 1262-1271	7.1	100
532	Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. <i>Blood Cancer Journal</i> , 2016 , 6, e472	7	32
531	Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. <i>American Journal of Hematology</i> , 2016 , 91, E12-4	7.1	17
530	The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. <i>Blood Reviews</i> , 2016 , 30, 453-459	11.1	70
529	Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2016 , 6, e436	7	4

528	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. <i>Blood Cancer Journal</i> , 2016 , 6, e414	7	16
527	Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2016 , 6, e427	7	14
526	Clinical and laboratory characteristics in congenital ANKRD26 mutation-associated thrombocytopenia: A detailed phenotypic study of a family. <i>Platelets</i> , 2016 , 27, 712-715	3.6	15
525	Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. <i>American Journal of Hematology</i> , 2016 , 91, 390-4	7.1	72
524	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2016 , 6, e385	7	83
523	CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value. <i>Leukemia</i> , 2016 , 30, 914-8	10.7	23
522	Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2016 , 6, e393	7	80
521	Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 259-72	6.4	19
520	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. <i>Blood Cancer Journal</i> , 2016 , 6, e405	7	24
519	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , 2016 , 128, 1123-1123	2.2	4
518	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , 2016 , 128, 2798-2798	2.2	3
517	Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. <i>Blood</i> , 2016 , 128, 3113-3113	2.2	2
516	Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. <i>Blood</i> , 2016 , 128, 3115-3115	2.2	1
515	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. <i>Blood</i> , 2016 , 128, 3604-3604	2.2	3
514	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. <i>Blood</i> , 2016 , 128, 4247-4247	2.2	2
513	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. <i>Blood</i> , 2016 , 128, 4248-4248	2.2	1
512	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. <i>Blood</i> , 2016 , 128, 4249-4249	2.2	2
511	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. <i>Blood</i> , 2016 , 128, 948-948	2.2	1

510	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. <i>Blood</i> , 2016 , 128, 1987-1987	2.2	0
509	Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. <i>Blood</i> , 2016 , 128, 3129-3129	2.2	
508	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. <i>Blood</i> , 2016 , 128, 5541-5541	2.2	
507	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. <i>Blood</i> , 2016 , 128, 300-300	2.2	
506	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. <i>Blood</i> , 2016 , 128, 4259-4259	2.2	
505	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. <i>Blood</i> , 2016 , 128, 5534-5534	2.2	0
504	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016 , 128, 1988-1988	2.2	
503	The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. <i>Blood</i> , 2016 , 128, 5542-5542	2.2	
502	Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016 , 128, 1989-1989	2.2	
501	The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia. <i>Blood</i> , 2016 , 128, 3120-3120	2.2	
500	Targeted deep sequencing in primary myelofibrosis. <i>Blood Advances</i> , 2016 , 1, 105-111	7.8	120
499	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFR mutation. <i>American Journal of Hematology</i> , 2016 , 91, E10-1	7.1	17
498	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. <i>American Journal of Hematology</i> , 2016 , 91, 492-8	7.1	55
497	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. <i>American Journal of Clinical Pathology</i> , 2016 , 146, 86-94	1.9	14
496	Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis. <i>American Journal of Hematology</i> , 2016 , 91, E6-7	7.1	
495	Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016 , 91, E296-7	7.1	6
494	Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. <i>American Journal of Hematology</i> , 2016 , 91, 888-93	7.1	47
493	Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. <i>Leukemia</i> , 2016 , 30, 1924-6	10.7	30

492	Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. <i>Annals of Hematology</i> , 2016 , 95, 1185-9	3	10
491	Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. <i>Blood Cancer Journal</i> , 2016 , 6, e415	7	8
490	Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. <i>Leukemia</i> , 2016 , 30, 2273-2275	10.7	16
489	The prognostic impact of bone marrow fibrosis in primary myelofibrosis. <i>American Journal of Hematology</i> , 2016 , 91, E454	7.1	3
488	Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016 , 91, 631-42	7.1	47
487	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. <i>British Journal of Haematology</i> , 2016 , 175, 534-536	4.5	19
486	Myeloproliferative neoplasms: A decade of discoveries and treatment advances. <i>American Journal of Hematology</i> , 2016 , 91, 50-8	7.1	108
485	Myelodysplastic syndromes: Contemporary review and how we treat. <i>American Journal of Hematology</i> , 2016 , 91, 76-89	7.1	119
484	Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management. <i>American Journal of Hematology</i> , 2016 , 91, 341-9	7.1	17
483	Myeloproliferative neoplasms: Morphology and clinical practice. <i>American Journal of Hematology</i> , 2016 , 91, 430-3	7.1	36
482	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. <i>American Journal of Hematology</i> , 2016 , 91, 503-6	7.1	37
481	Concurrent activating KIT mutations in systemic mastocytosis. <i>British Journal of Haematology</i> , 2016 , 173, 153-6	4.5	11
480	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2015 , 90, 162-73	7.1	166
479	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. <i>Blood Cancer Journal</i> , 2015 , 5, e270	7	21
478	Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. <i>Blood Cancer Journal</i> , 2015 , 5, e286	7	4
477	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia</i> , 2015 , 29, 741-4	10.7	33
476	Myeloproliferative Neoplasms: A Contemporary Review. <i>JAMA Oncology</i> , 2015 , 1, 97-105	13.4	195
475	New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. <i>American Journal of Hematology</i> , 2015 , 90, 683-5	7.1	13

474	Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. <i>Current Opinion in Hematology</i> , 2015 , 22, 171-6	3.3	15
473	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 643-51	13.4	242
472	Refractory anemia with ring sideroblasts and RARS with thrombocytosis. <i>American Journal of Hematology</i> , 2015 , 90, 549-59	7.1	31
471	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. <i>Blood Cancer Journal</i> , 2015 , 5, e333	7	89
470	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1623-38	6.4	10
469	A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2015 , 5, e335	7	67
468	ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. <i>Blood Cancer Journal</i> , 2015 , 5, e315	7	23
467	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. <i>Leukemia</i> , 2015 , 29, 2126-33	10.7	171
466	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. <i>New England Journal of Medicine</i> , 2015 , 373, 908-19	59.2	219
465	Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. <i>Blood Cancer Journal</i> , 2015 , 5, e337	7	77
464	Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1283-93	6.4	32
463	The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. <i>Leukemia</i> , 2015 , 29, 992-3	10.7	11
462	Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. <i>European Journal of Haematology</i> , 2015 , 94, 31-6	3.8	35
461	Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). <i>Leukemia</i> , 2015 , 29, 20-6	10.7	33
460	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. <i>Leukemia</i> , 2015 , 29, 498-500	10.7	14
459	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. <i>American Journal of Hematology</i> , 2015 , 90, 434-7	7.1	11
458	Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. <i>British Journal of Haematology</i> , 2015 , 171, 875-9	4.5	3
457	Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. <i>Blood Cancer Journal</i> , 2015 , 5, e369	7	123

456	ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. <i>American Journal of Hematology</i> , 2015 , 90, 653-6	7.1	58
455	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. <i>American Journal of Hematology</i> , 2015 , 90, 411-6	7.1	45
454	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. <i>Nature Medicine</i> , 2015 , 21, 1473-80	50.5	97
453	Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. <i>Blood Cancer Journal</i> , 2015 , 5, e366	7	129
452	Aberrant expression of CD123 (interleukin-3 receptor- β) on neoplastic mast cells. <i>Leukemia</i> , 2015 , 29, 1605-8	10.7	25
451	Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2015 , 5, e275	7	35
450	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 1599-1599	2.2	1
449	Spectrum of Mutations Associated with Hereditary Erythrocytosis. <i>Blood</i> , 2015 , 126, 2140-2140	2.2	1
448	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. <i>Blood</i> , 2015 , 126, 2801-2801	2.2	1
447	Peripheral Blood JAK2V617F Quantitative Assessment in Clinical Practice: Correlations Between Allele Burden and Clinical Phenotype. <i>Blood</i> , 2015 , 126, 2819-2819	2.2	1
446	Low Dose, Single Fraction, Whole Lung Irradiation for Extramedullary Hematopoiesis Associated with Myelofibrosis with Myeloid Metaplasia. <i>Blood</i> , 2015 , 126, 2820-2820	2.2	1
445	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. <i>Blood</i> , 2015 , 126, 350-350	2.2	1
444	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 354-354	2.2	9
443	Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 4078-4078	2.2	1
442	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. <i>Blood</i> , 2015 , 126, 55-55	2.2	3
441	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. <i>Blood</i> , 2015 , 126, 828-828	2.2	2
440	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). <i>Blood</i> , 2015 , 126, 4067-4067	2.2	
439	Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival. <i>Blood</i> , 2015 , 126, 1611-1611	2.2	

438	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015 , 126, 4062-4062	2.2	
437	Molecular Correlates of Anemia in Primary Myelofibrosis. <i>Blood</i> , 2015 , 126, 4068-4068	2.2	
436	CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. <i>Blood</i> , 2015 , 126, 2802-2802	2.2	
435	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. <i>Blood</i> , 2015 , 126, 2875-2875	2.2	
434	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2015 , 126, 2864-2864	2.2	
433	Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. <i>Blood</i> , 2015 , 126, 2805-2805	2.2	
432	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. <i>Blood</i> , 2015 , 126, 2882-2882	2.2	
431	Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 4055-4055	2.2	
430	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. <i>Leukemia</i> , 2014 , 28, 1494-500	10.7	211
429	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. <i>American Journal of Hematology</i> , 2014 , 89, 588-90	7.1	58
428	Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. <i>British Journal of Haematology</i> , 2014 , 165, 273-86	4.5	74
427	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. <i>American Journal of Hematology</i> , 2014 , 89, E121-4	7.1	145
426	Calreticulin mutations and long-term survival in essential thrombocythemia. <i>Leukemia</i> , 2014 , 28, 2300-3	10.7	79
425	Masked polycythemia vera (mPV): results of an international study. <i>American Journal of Hematology</i> , 2014 , 89, 52-4	7.1	103
424	Rethinking the diagnostic criteria of polycythemia vera. <i>Leukemia</i> , 2014 , 28, 1191-5	10.7	38
423	Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. <i>Leukemia</i> , 2014 , 28, 1363-5	10.7	42
422	An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. <i>Leukemia</i> , 2014 , 28, 1407-13	10.7	167
421	CALR mutation studies in chronic neutrophilic leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 450	7.1	26

420	CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. <i>Leukemia</i> , 2014 , 28, 1370-1	10.7	10
419	CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. <i>Leukemia</i> , 2014 , 28, 1472-7	10.7	381
418	U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. <i>Leukemia</i> , 2014 , 28, 431-3	10.7	56
417	The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. <i>Leukemia</i> , 2014 , 28, 485-96	10.7	179
416	Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. <i>Leukemia</i> , 2014 , 28, 2092-4	10.7	11
415	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. <i>Leukemia</i> , 2014 , 28, 1804-10	10.7	213
414	Altered expression of tumor suppressor PHF20 in myeloproliferative neoplasms. <i>Leukemia</i> , 2014 , 28, 1762-4	10.7	1
413	Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2014 , 89, 915-25	7.1	72
412	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. <i>Leukemia</i> , 2014 , 28, 1774-83	10.7	184
411	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. <i>Blood</i> , 2014 , 124, 2507-13; quiz 2615	2.2	424
410	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. <i>Blood</i> , 2014 , 124, 2465-6	2.2	105
409	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014 , 124, 3021-3	2.2	80
408	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. <i>Leukemia</i> , 2014 , 28, 2206-12	10.7	186
407	Definition and management of ruxolitinib treatment failure in myelofibrosis. <i>Blood Cancer Journal</i> , 2014 , 4, e268	7	25
406	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. <i>American Journal of Hematology</i> , 2014 , 89, 1111-5	7.1	104
405	Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. <i>Leukemia</i> , 2014 , 28, 1568-70	10.7	118
404	AKT is a therapeutic target in myeloproliferative neoplasms. <i>Leukemia</i> , 2013 , 27, 1882-90	10.7	51
403	CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. <i>Leukemia</i> , 2013 , 27, 1870-3	10.7	187

402	Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. <i>Leukemia</i> , 2013 , 27, 1617-20	10.7	44
401	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. <i>Leukemia</i> , 2013 , 27, 1504-10	10.7	151
400	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2013 , 88, 690-3	7.1	29
399	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013 , 122, 1395-8	2.2	218
398	Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2013 , 88, 141-50	7.1	89
397	Mutations and prognosis in primary myelofibrosis. <i>Leukemia</i> , 2013 , 27, 1861-9	10.7	520
396	Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2013 , 88, 507-16	7.1	92
395	Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. <i>American Journal of Hematology</i> , 2013 , 88, 2016-7	7.1	112
394	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. <i>Leukemia</i> , 2013 , 27, 2100-2	10.7	75
393	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. <i>Leukemia</i> , 2013 , 27, 1874-81	10.7	389
392	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013 , 121, 2393-401	2.2	89
391	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013 , 122, 104-104	2.2	3
390	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013 , 122, 108-108	2.2	30
389	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. <i>Blood</i> , 2013 , 122, 109-109	2.2	1
388	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. <i>Blood</i> , 2013 , 122, 1510-1510	2.2	2
387	Real-World Myelodysplastic Syndrome-unclassifiable And Its Comparison With Refractory Cytopenia With Multi-Lineage dysplasia And Refractory anemia Blood, 2013 , 122, 1574-1574	2.2	3
386	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. <i>Blood</i> , 2013 , 122, 1582-1582	2.2	1
385	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. <i>Blood</i> , 2013 , 122, 2821-2821	2.2	1

384	Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. <i>Blood</i> , 2013 , 122, 2830-2830	2.2	1
383	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , 2013 , 122, 394-394	2.2	13
382	Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). <i>Blood</i> , 2013 , 122, 4047-4047	2.2	4
381	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013 , 122, 4049-4049	2.2	1
380	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. <i>Blood</i> , 2013 , 122, 4067-4067	2.2	6
379	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. <i>Blood</i> , 2013 , 122, 662-662	2.2	10
378	BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. <i>Blood</i> , 2013 , 122, 664-664	2.2	15
377	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. <i>Blood</i> , 2013 , 122, 1587-1587	2.2	
376	Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis. <i>Blood</i> , 2013 , 122, 2824-2824	2.2	
375	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. <i>Blood</i> , 2013 , 122, 4060-4060	2.2	
374	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. <i>Blood</i> , 2013 , 122, 4048-4048	2.2	
373	Masked Polycythemia Vera (mPV): Results Of An International Study. <i>Blood</i> , 2013 , 122, 1581-1581	2.2	
372	Pruritus In Primary Myelofibrosis: Treatment Attempts, Response and Outcomes. <i>Blood</i> , 2013 , 122, 4081-4081	2.2	
371	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 5000-5000	2.2	
370	Long-term outcome of pomalidomide therapy in myelofibrosis. <i>American Journal of Hematology</i> , 2012 , 87, 66-8	7.1	55
369	Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012 , 87, 285-93	7.1	125
368	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. <i>Blood</i> , 2012 , 119, 2239-41	2.2	73
367	A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. <i>Blood</i> , 2012 , 120, 1197-201	2.2	172

366	Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. <i>Blood</i> , 2012 , 119, 5674-7	2.2	59
365	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. <i>Blood</i> , 2012 , 120, 4168-71	2.2	128
364	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. <i>Blood</i> , 2012 , 119, 569-72	2.2	164
363	One thousand patients with primary myelofibrosis: the mayo clinic experience. <i>Mayo Clinic Proceedings</i> , 2012 , 87, 25-33	6.4	137
362	JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. <i>Blood</i> , 2012 , 119, 2721-30	2.2	129
361	Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). <i>Blood</i> , 2012 , 120, 5128-33; quiz 5252	2.2	340
360	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. <i>Blood</i> , 2012 , 120, 569-71	2.2	60
359	Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. <i>Leukemia Research</i> , 2012 , 36, 1481-9	2.7	13
358	Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. <i>Leukemia</i> , 2012 , 26, 716-9	10.7	112
357	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. <i>Leukemia</i> , 2012 , 26, 101-5	10.7	112
356	IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. <i>Leukemia</i> , 2012 , 26, 475-80	10.7	129
355	Long-term follow-up of FIP1L1-PDGFRα-mutated patients with eosinophilia: survival and clinical outcome. <i>Leukemia</i> , 2012 , 26, 2439-41	10.7	43
354	SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. <i>Leukemia</i> , 2012 , 26, 1135-7	10.7	81
353	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. <i>Blood</i> , 2012 , 120, 1731-1731	2.2	1
352	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. <i>Blood</i> , 2012 , 120, 178-178	2.2	7
351	Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.. <i>Blood</i> , 2012 , 120, 2836-2836	2.2	1
350	A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. <i>Blood</i> , 2012 , 120, 2837-2837	2.2	6
349	Splenectomy for Massive Splenomegaly Associated with Myelofibrosis: Outcomes From 63 Patients At Mayo Clinic.. <i>Blood</i> , 2012 , 120, 2848-2848	2.2	1

348	Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. <i>Blood</i> , 2012 , 120, 2851-2851	2.2	4
347	Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.. <i>Blood</i> , 2012 , 120, 2867-2867	2.2	2
346	Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2012 , 120, 424-424	2.2	3
345	Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. <i>Blood</i> , 2012 , 120, 1751-1751	2.2	
344	Polycythemia Vera and Chronic Idiopathic Myelofibrosis CD34+ Cells Preferentially Traffic to Splenic Niches. <i>Blood</i> , 2012 , 120, 1750-1750	2.2	
343	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. <i>Blood</i> , 2012 , 120, 1711-1711	2.2	1
342	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with $\geq 1\%$ Ring Sideroblasts.. <i>Blood</i> , 2012 , 120, 2803-2803	2.2	
341	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. <i>Blood</i> , 2012 , 120, 1726-1726	2.2	
340	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. <i>Blood</i> , 2012 , 120, 3790-3790	2.2	
339	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. <i>Blood</i> , 2012 , 120, 430-430	2.2	2
338	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012 , 120, 423-423	2.2	2
337	Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.. <i>Blood</i> , 2012 , 120, 2831-2831	2.2	
336	Comparison of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. <i>Blood</i> , 2012 , 120, 2852-2852	2.2	
335	Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort. <i>Blood</i> , 2012 , 120, 1729-1729	2.2	1
334	The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. <i>Blood</i> , 2012 , 120, 1742-1742	2.2	
333	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. <i>Blood</i> , 2012 , 120, 2849-2849	2.2	
332	Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 1188-91	6.4	172
331	JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. <i>Blood Reviews</i> , 2011 , 25, 229-37	11.1	42

330	Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 673-674	4.5	9
329	Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. <i>Blood</i> , 2011 , 117, 5612-5	2.2	56
328	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. <i>Blood</i> , 2011 , 118, 401-8	2.2	215
327	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. <i>Blood</i> , 2011 , 117, 5857-9	2.2	295
326	Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. <i>Blood</i> , 2011 , 118, 4595-8	2.2	56
325	Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. <i>Leukemia</i> , 2011 , 25, 82-8	10.7	150
324	JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. <i>Leukemia</i> , 2011 , 25, 218-25	10.7	105
323	Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. <i>Leukemia</i> , 2011 , 25, 1200-2	10.7	178
322	DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. <i>Leukemia</i> , 2011 , 25, 1219-20	10.7	131
321	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011 , 29, 761-70	2.2	589
320	Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2011 , 86, 292-301	7.1	33
319	Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. <i>American Journal of Hematology</i> , 2011 , 86, 610-1	7.1	61
318	Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011 , 86, 1017-26	7.1	42
317	Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. <i>Cancer</i> , 2011 , 117, 4869-4877	6.4	44
316	DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. <i>Journal of Clinical Oncology</i> , 2011 , 29, 392-7	2.2	677
315	How I treat myelofibrosis. <i>Blood</i> , 2011 , 117, 3494-504	2.2	105
314	Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1356-63	2.2	402
313	Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. <i>Journal of Molecular Diagnostics</i> , 2011 , 13, 461-6	5.1	16

312	Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3179-84	2.2	355
311	Long-term outcome of treatment with ruxolitinib in myelofibrosis. <i>New England Journal of Medicine</i> , 2011 , 365, 1455-7	59.2	121
310	A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). <i>Blood</i> , 2011 , 118, 1746-1746	2.2	1
309	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. <i>Blood</i> , 2011 , 118, 1759-1759	2.2	0
308	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. <i>Blood</i> , 2011 , 118, 277-277	2.2	4
307	SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis,. <i>Blood</i> , 2011 , 118, 3838-3838	2.2	8
306	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. <i>Blood</i> , 2011 , 118, 3839-3839	2.2	4
305	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011 , 118, 3849-3849	2.2	10
304	Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. <i>Blood</i> , 2011 , 118, 3850-3850	2.2	1
303	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. <i>Blood</i> , 2011 , 118, 460-460	2.2	0
302	Induction of Megakaryocyte Polyploidization in Combination with JAK Inhibition As a Novel Therapeutic Strategy for Myeloproliferative Neoplasms. <i>Blood</i> , 2011 , 118, 64-64	2.2	2
301	Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases. <i>Blood</i> , 2011 , 118, 2806-2806	2.2	
300	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. <i>Blood</i> , 2011 , 118, 3795-3795	2.2	
299	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. <i>Blood</i> , 2011 , 118, 3803-3803	2.2	
298	Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 5158-5158	2.2	
297	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. <i>Blood</i> , 2011 , 118, 1752-1752	2.2	1
296	Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients,. <i>Blood</i> , 2011 , 118, 3846-3846	2.2	
295	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. <i>Blood</i> , 2011 , 118, 3833-3833	2.2	

294	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 1756-1756	2.2	
293	Inhibition of AKT Signaling Potently Inhibits the Growth of JAK and MPL-Mutant Cells in the Myeloproliferative Neoplasms In Vitro and In Vivo,. <i>Blood</i> , 2011 , 118, 3862-3862	2.2	
292	Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm. <i>Blood</i> , 2011 , 118, 5148-5148	2.2	
291	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. <i>Blood</i> , 2011 , 118, 971-971	2.2	
290	Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. <i>Blood</i> , 2011 , 118, 5154-5154	2.2	
289	CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. <i>Blood</i> , 2011 , 118, 2807-2807	2.2	
288	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. <i>Blood</i> , 2011 , 118, 1751-1751	2.2	
287	Polycythemia vera-associated pruritus and its management. <i>European Journal of Clinical Investigation</i> , 2010 , 40, 828-34	4.6	48
286	JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. <i>Leukemia</i> , 2010 , 24, 105-9	10.7	99
285	The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. <i>Leukemia</i> , 2010 , 24, 110-4	10.7	56
284	MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. <i>Leukemia</i> , 2010 , 24, 859-60	10.7	21
283	WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. <i>Leukemia</i> , 2010 , 24, 1283-9	10.7	72
282	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. <i>Leukemia</i> , 2010 , 24, 1302-9	10.7	266
281	LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. <i>Leukemia</i> , 2010 , 24, 1713-8	10.7	156
280	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. <i>Leukemia</i> , 2010 , 24, 1128-38	10.7	435
279	Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. <i>American Journal of Clinical Pathology</i> , 2010 , 133, 942-8	1.9	22
278	LNK mutations in JAK2 mutation-negative erythrocytosis. <i>New England Journal of Medicine</i> , 2010 , 363, 1189-90	59.2	118
277	Targeted therapy in KITD816V-positive mastocytosis: waiting for proof-of-principle. <i>Leukemia and Lymphoma</i> , 2010 , 51, 360-2	1.9	2

276	Myelodysplastic syndromes--many new drugs, little therapeutic progress. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 1042-5	6.4	11
275	Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 158-64	6.4	118
274	Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. <i>Leukemia and Lymphoma</i> , 2010 , 51, 576-82	1.9	8
273	Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. <i>New England Journal of Medicine</i> , 2010 , 363, 1117-27	59.2	906
272	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. <i>Blood</i> , 2010 , 116, 2857-8	2.2	133
271	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). <i>Blood</i> , 2010 , 115, 1703-8	2.2	645
270	Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. <i>American Journal of Hematology</i> , 2010 , 85, 14-7	7.1	30
269	Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. <i>American Journal of Hematology</i> , 2010 , 85, 93-4	7.1	10
268	Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis. <i>Blood</i> , 2010 , 115, 745-746	2.2	
267	Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. <i>European Journal of Haematology</i> , 2010 , 85, 192-9	3.8	22
266	Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. <i>American Journal of Hematology</i> , 2010 , 85, 160-3	7.1	19
265	Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. <i>American Journal of Hematology</i> , 2010 , 85, 545	7.1	36
264	Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. <i>American Journal of Hematology</i> , 2010 , 85, 808-10	7.1	16
263	Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. <i>Blood</i> , 2010 , 116, 3068-3068	2.2	1
262	Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. <i>Blood</i> , 2010 , 116, 3070-3070	2.2	4
261	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. <i>Blood</i> , 2010 , 116, 4105-4105	2.2	1
260	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. <i>Blood</i> , 2010 , 116, 4112-4112	2.2	2
259	A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis. <i>Blood</i> , 2010 , 116, 630-630	2.2	10

258	Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients. <i>Blood</i> , 2010 , 116, 5060-5060	2.2	
257	DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. <i>Blood</i> , 2010 , 116, 4104-4104	2.2	1
256	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. <i>Blood</i> , 2010 , 116, 4095-4095	2.2	
255	Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients. <i>Blood</i> , 2010 , 116, 4122-4122	2.2	
254	Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients. <i>Blood</i> , 2010 , 116, 5053-5053	2.2	
253	A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. <i>Blood</i> , 2010 , 116, 4109-4109	2.2	1
252	Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype. <i>Blood</i> , 2010 , 116, 3069-3069	2.2	
251	Monosomal Karyotype In Myelodysplastic Syndromes, with or without Monosomy 7 or 5, Is Prognostically Worse Than An Otherwise Complex Karyotype. <i>Blood</i> , 2010 , 116, 2918-2918	2.2	
250	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 4009-4009	2.2	
249	Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 215-37	5.6	40
248	Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. <i>European Journal of Haematology</i> , 2009 , 82, 350-3	3.8	74
247	Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. <i>European Journal of Haematology</i> , 2009 , 83, 17-21	3.8	53
246	Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. <i>European Journal of Haematology</i> , 2009 , 83, 154-5	3.8	66
245	Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. <i>American Journal of Hematology</i> , 2009 , 84, 265-7	7.1	54
244	Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. <i>American Journal of Hematology</i> , 2009 , 84, 629-30	7.1	27
243	Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. <i>American Journal of Hematology</i> , 2009 , 84, 790-4	7.1	135
242	The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. <i>Cancer</i> , 2009 , 115, 3842-7	6.4	180
241	Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. <i>Cancer</i> , 2009 , 115, 5740-5	6.4	51

240	Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFR α correlates. <i>Leukemia</i> , 2009 , 23, 900-4	10.7	221
239	TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. <i>Leukemia</i> , 2009 , 23, 905-11	10.7	351
238	The complete evaluation of erythrocytosis: congenital and acquired. <i>Leukemia</i> , 2009 , 23, 834-44	10.7	83
237	Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. <i>Leukemia</i> , 2009 , 23, 1343-5	10.7	219
236	Myelodysplastic syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 1872-85	59.2	527
235	Myeloproliferative neoplasms: thrombophilic clonal stem cell diseases. <i>Cancer Treatment and Research</i> , 2009 , 148, 157-79	3.5	3
234	JAK2V617F: more than a clonal marker?. <i>Leukemia and Lymphoma</i> , 2009 , 50, 154-5	1.9	
233	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , 2009 , 113, 2895-901	2.2	905
232	Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 627-37	19.4	102
231	The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. <i>Blood</i> , 2009 , 114, 937-51	2.2	3222
230	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. <i>Blood</i> , 2009 , 113, 5727-36	2.2	399
229	IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis.. <i>Blood</i> , 2009 , 114, 2909-2909	2.2	1
228	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 925-925	2.2	1
227	A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT).. <i>Blood</i> , 2009 , 114, 3891-3891	2.2	
226	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. <i>Leukemia</i> , 2008 , 22, 1299-307	10.7	239
225	Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. <i>Leukemia</i> , 2008 , 22, 437-8	10.7	355
224	The history of myeloproliferative disorders: before and after Dameshek. <i>Leukemia</i> , 2008 , 22, 3-13	10.7	59
223	Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. <i>Leukemia</i> , 2008 , 22, 14-22	10.7	780

222	Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. <i>Leukemia</i> , 2008 , 22, 756-61	10.7	229
221	20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. <i>European Journal of Haematology</i> , 2008 , 80, 386-90	3.8	27
220	JAK and MPL mutations in myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2008 , 49, 388-97	1.9	70
219	Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2231-2	1.9	2
218	Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1225-7	1.9	2
217	Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. <i>Blood</i> , 2008 , 111, 2785-9	2.2	115
216	Risk factors for leukemic transformation in patients with primary myelofibrosis. <i>Cancer</i> , 2008 , 112, 2726-32	6.2	112
215	Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. <i>American Journal of Hematology</i> , 2008 , 83, 491-7	7.1	66
214	Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. <i>American Journal of Hematology</i> , 2008 , 83, 611-3	7.1	65
213	Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. <i>American Journal of Hematology</i> , 2008 , 83, 708-13	7.1	24
212	Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424. <i>Blood</i> , 2008 , 112, 2802-2802	2.2	10
211	Primary myelofibrosis. <i>Cancer Treatment and Research</i> , 2008 , 142, 29-49	3.5	9
210	Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 599-604	6.4	25
209	Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. <i>Cancer</i> , 2007 , 109, 2083-8	6.4	59
208	Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. <i>Leukemia Research</i> , 2007 , 31, 1503-9	2.7	73
207	Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. <i>Leukemia</i> , 2007 , 21, 270-6	10.7	161
206	Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. <i>Leukemia</i> , 2007 , 21, 1827-8	10.7	106
205	Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. <i>Leukemia</i> , 2007 , 21, 1960-3	10.7	226

204	Oncogenes in myeloproliferative disorders. <i>Cell Cycle</i> , 2007 , 6, 550-66	4.7	129
203	JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications. <i>New England Journal of Medicine</i> , 2007 , 356, 444-5	59.2	36
202	Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 313-20	5.3	157
201	The granulocyte connection in MPD-associated thrombosis. <i>Blood</i> , 2007 , 109, 2270-2271	2.2	0
200	JAK2 mutations and clinical practice in myeloproliferative neoplasms. <i>Cancer Journal (Sudbury, Mass)</i> , 2007 , 13, 366-71	2.2	26
199	The diagnostic interface between histology and molecular tests in myeloproliferative disorders. <i>Current Opinion in Hematology</i> , 2007 , 14, 115-22	3.3	25
198	Suppressors of cytokine signaling and regulation of clonal erythropoiesis. <i>Leukemia and Lymphoma</i> , 2007 , 48, 7-8	1.9	1
197	Neither Serum Ferritin Nor Number of Red Blood Cell Transfusions Affect Overall Survival in Refractory Anemia with Ringed Sideroblasts.. <i>Blood</i> , 2007 , 110, 2454-2454	2.2	1
196	Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.. <i>Blood</i> , 2007 , 110, 3543-3543	2.2	8
195	Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.. <i>Blood</i> , 2007 , 110, 3546-3546	2.2	2
194	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. <i>Blood</i> , 2007 , 110, 558-558	2.2	17
193	Platelet Count Is an IPSS-Independent Risk Factor Predicting Survival in Refractory Anemia with Ringed Sideroblasts.. <i>Blood</i> , 2007 , 110, 2455-2455	2.2	
192	Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.. <i>Blood</i> , 2007 , 110, 3545-3545	2.2	
191	The Presence of the JAK2V617F Mutation in Primary Myelofibrosis and Its Allele Burden in Polycythemia Vera Predict Chemosensitivity to Hydroxyurea.. <i>Blood</i> , 2007 , 110, 3539-3539	2.2	
190	Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.. <i>Blood</i> , 2007 , 110, 3504-3504	2.2	
189	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≤ 10 g/dL.. <i>Blood</i> , 2007 , 110, 3555-3555	2.2	
188	Peripheral Blood Cytogenetic Studies in Myelofibrosis: Overall Yield and Comparison with Bone Marrow Cytogenetic Studies. <i>Blood</i> , 2007 , 110, 1547-1547	2.2	
187	Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival.. <i>Blood</i> , 2007 , 110, 676-676	2.2	

186	Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.. <i>Blood</i> , 2007 , 110, 2550-2550	2.2	
185	Early Peripheral Blood Blast Clearance during Induction Chemotherapy for Acute Myeloid Leukemia (AML) Predicts Superior Relapse-Free Survival.. <i>Blood</i> , 2007 , 110, 1848-1848	2.2	2
184	JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.. <i>Blood</i> , 2007 , 110, 3191-3191	2.2	
183	Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.. <i>Blood</i> , 2007 , 110, 556-556	2.2	1
182	The recent advances in classic BCR-ABL-negative myeloproliferative disorders. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 113-5	0.6	
181	Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. <i>European Journal of Haematology</i> , 2006 , 77, 327-33	3.8	39
180	The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. <i>Cancer</i> , 2006 , 106, 631-5	6.4	187
179	Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. <i>Cancer</i> , 2006 , 106, 1739-43	6.4	18
178	Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. <i>Cancer</i> , 2006 , 106, 2406-11	6.4	20
177	Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. <i>Cancer</i> , 2006 , 107, 361-70	6.4	148
176	Genomics basics: DNA structure, gene expression, cloning, genetic mapping, and molecular tests. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2006 , 10, 282-90	1.4	5
175	Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. <i>Hematology American Society of Hematology Education Program</i> , 2006 , 2006, 240-5	3.1	58
174	Atypical myeloproliferative disorders: diagnosis and management. <i>Mayo Clinic Proceedings</i> , 2006 , 81, 553-63	6.4	38
173	Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. <i>Mayo Clinic Proceedings</i> , 2006 , 81, 159-66	6.4	269
172	Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1724-5	1.9	3
171	Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2055-61	1.9	18
170	Iron chelation therapy for myelodysplastic syndrome: if and when. <i>Mayo Clinic Proceedings</i> , 2006 , 81, 197-8	6.4	9
169	Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 365-85	4.2	30

168	The diagnosis of polycythemia vera: new tests and old dictums. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 455-69	4.2	10
167	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2006 , 108, 1158-64	2.2	211
166	Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?. <i>Blood</i> , 2006 , 108, 2493-4	2.2	67
165	Essential thrombocythemia: scientific advances and current practice. <i>Current Opinion in Hematology</i> , 2006 , 13, 93-8	3.3	20
164	New insights into the pathogenesis and drug treatment of myelofibrosis. <i>Current Opinion in Hematology</i> , 2006 , 13, 87-92	3.3	18
163	Eosinophilia: secondary, clonal and idiopathic. <i>British Journal of Haematology</i> , 2006 , 133, 468-92	4.5	196
162	Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. <i>Bone Marrow Transplantation</i> , 2006 , 37, 1003-8	4.4	55
161	Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. <i>Leukemia Research</i> , 2006 , 30, 677-80	2.7	9
160	FIP1L1-PDGFR α in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. <i>Leukemia Research</i> , 2006 , 30, 965-70	2.7	110
159	Mutation screening for JAK2V617F: when to order the test and how to interpret the results. <i>Leukemia Research</i> , 2006 , 30, 739-44	2.7	29
158	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. <i>Blood</i> , 2006 , 108, 2680-2680	2.2	3
157	Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.. <i>Blood</i> , 2006 , 108, 300-300	2.2	4
156	Dasatinib (Sprycel) [®] Therapy for Patients with Systemic Mastocytosis.. <i>Blood</i> , 2006 , 108, 3627-3627	2.2	3
155	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. <i>Blood</i> , 2006 , 108, 116-116	2.2	
154	Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders.. <i>Blood</i> , 2006 , 108, 661-661	2.2	
153	The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR β -Expressing Cells through Caspase-Dependent Cleavage of MCL-1.. <i>Blood</i> , 2006 , 108, 4882-4882	2.2	
152	Efficacy of Conventional Cytogenetics and FISH for EGR1 To Detect Deletion 5q in Hematological Disorders and To Assess Response to Treatment with Lenalidomide.. <i>Blood</i> , 2006 , 108, 2351-2351	2.2	
151	Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia.. <i>Blood</i> , 2006 , 108, 3629-3629	2.2	

150	Alemtuzumab (CAMPATH-1H) Is Effective Therapy for Hypereosinophilic Syndrome (HES).. <i>Blood</i> , 2006 , 108, 4902-4902	2.2	
149	Additional Cytogenetic Abnormalities and/or Philadelphia Chromosome Metaphase Mosaicism Might Adversely Influence Survival and Imatinib Response in Chronic Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 4783-4783	2.2	
148	All-Trans Retinoic Acid Syndrome Mimicking ST Segment Elevation Myocardial Infarction.. <i>Blood</i> , 2006 , 108, 4571-4571	2.2	
147	Idiopathic Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFR α Status, and Clinical Course.. <i>Blood</i> , 2006 , 108, 2701-2701	2.2	
146	Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 75-83	6.4	91
145	The indolent natural history of essential thrombocythemia: a challenge to new drug development. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 97-8	6.4	4
144	bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 1220-32	6.4	36
143	How to interpret and pursue an abnormal complete blood cell count in adults. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 923-36	6.4	109
142	Introduction to a cancer symposium for the practitioner. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 1085-6	6.4	4
141	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 390-402	6.4	46
140	Pathogenesis of myelofibrosis with myeloid metaplasia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8520-30	2.2	211
139	Polycythemia vera: scientific advances and current practice. <i>Seminars in Hematology</i> , 2005 , 42, 206-20	4	52
138	The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 947-58	6.4	101
137	Mutant Kit: thwarting the message down below. <i>Blood</i> , 2005 , 105, 2240-2241	2.2	
136	Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2005 , 128, 275-90	4.5	371
135	JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. <i>British Journal of Haematology</i> , 2005 , 131, 208-13	4.5	257
134	WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. <i>Leukemia</i> , 2005 , 19, 313-7	10.7	77
133	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. <i>Cancer Cell</i> , 2005 , 7, 387-97	24.3	2353

132	Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. <i>Cancer</i> , 2005 , 104, 213-5	6.4	31
131	Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. <i>Cancer</i> , 2005 , 104, 1656-60	6.4	52
130	A critical review of anagrelide therapy in essential thrombocythemia and related disorders. <i>Leukemia and Lymphoma</i> , 2005 , 46, 641-50	1.9	20
129	Modern diagnosis and treatment of primary eosinophilia. <i>Acta Haematologica</i> , 2005 , 114, 52-60	2.7	39
128	The Role of Stem Cell Mobilization Regimen on Lymphocyte Collection Yield and Survival after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 1174-1174 ^{2.2}		1
127	The Increasing Relevance of Copper Deficiency in Hematological Practice.. <i>Blood</i> , 2005 , 106, 1679-1679	2.2	2
126	Cytogenetic Profile, JAK2V617F Mutational Status, and Response to Drug Therapy in Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2005 , 106, 2591-2591	2.2	
125	Presence of Unfavorable Cytogenetic Abnormalities Is the Strongest Predictor of Poor Survival in Secondary Myelofibrosis.. <i>Blood</i> , 2005 , 106, 2585-2585	2.2	
124	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 5420-5420	2.2	
123	Low Incidence of FIP1L1-PDGFR in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. <i>Blood</i> , 2005 , 106, 2590-2590	2.2	
122	Microcytosis in Myelofibrosis with Myeloid Metaplasia: Prevalence and Clinical Correlates.. <i>Blood</i> , 2005 , 106, 4947-4947	2.2	
121	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. <i>Blood</i> , 2005 , 106, 5422-5422	2.2	
120	The rise and fall of red cell mass measurement in polycythemia vera. <i>Psychophysiology</i> , 2005 , 4, 213-7		12
119	JAK2 in myeloproliferative disorders is not just another kinase. <i>Cell Cycle</i> , 2005 , 4, 1053-6	4.7	13
118	Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. <i>International Journal of Hematology</i> , 2004 , 79, 441-7	2.3	12
117	The spleen in myelofibrosis with myeloid metaplasia. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 503	6.4	1
116	Primer on medical genomics. The end of the beginning. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 659-60	6.4	1
115	Breast peau d'orange from large cell lymphoma. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 187	6.4	

114	Clinical, genetic, and therapeutic insights into systemic mast cell disease. <i>Current Opinion in Hematology</i> , 2004 , 11, 58-64	3.3	64
113	Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. <i>Blood</i> , 2004 , 103, 3547-8	2.2	39
112	A Phase II Study of CC-5013 Treatment for Myelofibrosis with Myeloid Metaplasia: A Preliminary Report.. <i>Blood</i> , 2004 , 104, 1505-1505	2.2	3
111	Red Cell Mass Measurement in Polycythemia: Evaluation of Performance and Added Value.. <i>Blood</i> , 2004 , 104, 1525-1525	2.2	2
110	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004 , 104, 2927-2927	2.2	1
109	Blood CD34 Count in Myelofibrosis with Myeloid Metaplasia: A Prospective Evaluation of Prognostic Value in 94 Patients.. <i>Blood</i> , 2004 , 104, 662-662	2.2	1
108	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004 , 104, 892-892	2.2	1
107	Clinical and Laboratory Correlative Studies of Neutrophil PRV-1 Expression: A Prospective Study in 141 Subjects.. <i>Blood</i> , 2004 , 104, 1519-1519	2.2	
106	Allogeneic Stem Cell Transplantation (SCT) in Untreated First Relapse or Following Re-Induction Chemotherapy for Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004 , 104, 5143-5143	2.2	
105	Somatic Point Mutations in RUNX1/CBFA2/AML1 Are Common in High-Risk Myelodysplastic Syndrome, but Not in Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2004 , 104, 2438-2438	2.2	
104	Acquired Pure Red Cell Aplasia Associated with Clonal T-Cell Receptor (TCR) Gene Rearrangements with and without Pathologic Features of T-Cell Large Granular Lymphocytic Leukemia (T-LGLL).. <i>Blood</i> , 2004 , 104, 2819-2819	2.2	
103	A Phase I Trial of Autologous Dendritic Cell Therapy for Chronic Myelogenous Leukemia.. <i>Blood</i> , 2004 , 104, 2931-2931	2.2	1
102	Neutrophil and Eosinophil PRV-1 Expression in Atypical Myeloproliferative Disorders.. <i>Blood</i> , 2004 , 104, 1521-1521	2.2	
101	Systemic mastocytosis: current concepts and treatment advances. <i>Psychophysiology</i> , 2004 , 3, 197-202		27
100	Schistocytes on the peripheral blood smear. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 809	6.4	2
99	A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2003 , 101, 2534-41	2.2	255
98	Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. <i>Leukemia Research</i> , 2003 , 27, 775-82	2.7	25
97	Polycythemia vera: a comprehensive review and clinical recommendations. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 174-94	6.4	118

96	Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 1223-33	6.4	245
95	Anemia in adults: a contemporary approach to diagnosis. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 1274-80	6.4	84
94	Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new. <i>Seminars in Hematology</i> , 2003 , 40, 18-21	4	9
93	The forgotten myeloproliferative disorder: myeloid metaplasia. <i>Oncologist</i> , 2003 , 8, 225-31	5.7	43
92	A contemporary approach to the diagnosis and management of polycythemia vera. <i>Psychophysiology</i> , 2003 , 2, 237-41		12
91	Thalidomide treatment in myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2002 , 117, 288-96	4.5	97
90	Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2002 , 118, 813-6	4.5	73
89	Current management of polycythemia vera. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1-7	1.9	7
88	Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. <i>Blood</i> , 2002 , 99, 2627	2.2	81
87	Primer on medical genomics part II: Background principles and methods in molecular genetics. <i>Mayo Clinic Proceedings</i> , 2002 , 77, 785-808	6.4	25
86	Primer on medical genomics. Part III: Microarray experiments and data analysis. <i>Mayo Clinic Proceedings</i> , 2002 , 77, 927-40	6.4	48
85	Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed. <i>Blood</i> , 2001 , 97, 3321-2	2.2	2
84	Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2001 , 97, 3665-7	2.2	36
83	Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2001 , 97, 1896	2.2	59
82	Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. <i>Blood</i> , 2001 , 98, 483-5	2.2	79
81	A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. <i>Annals of Hematology</i> , 2001 , 80, 166-9	3	52
80	The pathogenesis of chronic myeloproliferative diseases. <i>International Journal of Hematology</i> , 2001 , 73, 170-6	2.3	9
79	Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. <i>British Journal of Haematology</i> , 2001 , 115, 619-21	4.5	169

78	Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. <i>Blood Reviews</i> , 2001 , 15, 121-31	11.1	72
77	Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 997-9	4.4	15
76	Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. <i>Leukemia</i> , 2001 , 15, 35-40	10.7	55
75	A single institutional experience with 43 pregnancies in essential thrombocythemia. <i>European Journal of Haematology</i> , 2001 , 66, 152-9	3.8	80
74	Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1229-34	1.9	2
73	Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1243-53	1.9	5
72	Palliative splenectomy in myelofibrosis with myeloid metaplasia. <i>Leukemia and Lymphoma</i> , 2001 , 42, 901-11	1.9	19
71	Treatment of systemic mast-cell disease with cladribine. <i>New England Journal of Medicine</i> , 2001 , 344, 307-9	59.2	130
70	Acute leukemia during pregnancy: a single institutional experience with 17 cases. <i>Leukemia and Lymphoma</i> , 2001 , 41, 571-7	1.9	69
69	A long-term retrospective study of young women with essential thrombocythemia. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 22-8	6.4	110
68	Long-term use of anagrelide in young patients with essential thrombocythemia. <i>Blood</i> , 2001 , 97, 863-6	2.2	129
67	Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. <i>European Journal of Haematology</i> , 2000 , 65, 170-4	3.8	41
66	Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. <i>Blood</i> , 2000 , 95, 2226-2233	2.2	224
65	Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. <i>Blood</i> , 2000 , 96, 3644-3646	2.2	30
64	Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. <i>American Journal of Clinical Pathology</i> , 2000 , 113, 212-8	1.9	34
63	Myelofibrosis with myeloid metaplasia. <i>New England Journal of Medicine</i> , 2000 , 342, 1255-65	59.2	640
62	Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. <i>Blood</i> , 2000 , 96, 3644-3646	2.2	3
61	Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. <i>Blood</i> , 2000 , 96, 1582-1584	2.2	1

60	Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. <i>Blood</i> , 2000 , 95, 2226-33	2.2	50
59	Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. <i>Blood</i> , 2000 , 96, 771-2	2.2	8
58	Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. <i>Blood</i> , 2000 , 96, 1582-4	2.2	2
57	Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 1999 , 106, 682-8	4.5	36
56	A long-term study of patients with chronic natural killer cell lymphocytosis. <i>British Journal of Haematology</i> , 1999 , 106, 960-6	4.5	76
55	Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. <i>American Journal of Hematology</i> , 1999 , 61, 10-5	7.1	251
54	Concurrent inflammatory bowel disease and myelodysplastic syndromes. <i>Inflammatory Bowel Diseases</i> , 1999 , 5, 98-103	4.5	29
53	Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995 1999 , 61, 10		7
52	Introduction: overview of chronic myeloproliferative disorders. <i>Seminars in Hematology</i> , 1999 , 36, 1-2	4	
51	Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. <i>Seminars in Hematology</i> , 1999 , 36, 3-8	4	1
50	Pregnancy and thrombocythemia. <i>American Journal of Hematology</i> , 1998 , 57, 181-2	7.1	1
49	Anemia after orchiectomy. <i>American Journal of Hematology</i> , 1998 , 59, 230-3	7.1	54
48	Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 1998 , 103, 505-11	4.5	115
47	Is Hydroxyurea Leukemogenic in Essential Thrombocythemia?. <i>Blood</i> , 1998 , 92, 1459-1461	2.2	16
46	Is Hydroxyurea Leukemogenic in Essential Thrombocythemia?. <i>Blood</i> , 1998 , 92, 1459-1461	2.2	1
45	Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review 1998 , 59, 161		2
44	Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review 1998 , 59, 161		1
43	Bone marrow granulomas associated with chronic natural killer cell lymphocytosis. <i>American Journal of Hematology</i> , 1997 , 54, 258-62	7.1	8

42	New drugs in essential thrombocythemia and polycythemia vera. <i>Blood Reviews</i> , 1997 , 11, 1-7	11.1	32
41	The effects of anagrelide on human megakaryocytopoiesis. <i>British Journal of Haematology</i> , 1997 , 99, 174-80	4.5	67
40	2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 1997 , 99, 352-7	4.5	57
39	Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report. <i>American Journal of Hematology</i> , 1997 , 55, 148-55	7.1	28
38	Chronic natural killer cell lymphocytosis. <i>Leukemia and Lymphoma</i> , 1996 , 20, 245-8	1.9	24
37	Current perspective in agnogenic myeloid metaplasia. <i>Leukemia and Lymphoma</i> , 1996 , 22 Suppl 1, 169-71	1.9	11
36	Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities [see comments]. <i>Blood</i> , 1996 , 87, 3000-3006	2.2	99
35	Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. <i>American Journal of Clinical Pathology</i> , 1996 , 106, 457-61	1.9	35
34	Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha. <i>American Journal of Hematology</i> , 1996 , 52, 231-3	7.1	4
33	Fever of unknown origin associated with chronic natural killer cell lymphocytosis. <i>American Journal of Hematology</i> , 1996 , 53, 56	7.1	1
32	Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. <i>British Journal of Haematology</i> , 1996 , 93, 406-8	4.5	31
31	Natural leukocyte interferon- β therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon- β 1996 , 52, 231		3
30	Agnogenic myeloid metaplasia. <i>Seminars in Oncology</i> , 1995 , 22, 327-33	5.5	30
29	Primary thrombocythemia. <i>Seminars in Oncology</i> , 1995 , 22, 334-40	5.5	36
28	Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. <i>Journal of Clinical Oncology</i> , 1994 , 12, 569-74	2.2	36
27	Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?. <i>Blood</i> , 1994 , 84, 1620-1627	2.2	194
26	Chronic natural killer cell lymphocytosis: a descriptive clinical study. <i>Blood</i> , 1994 , 84, 2721-2725	2.2	125
25	The 5q- syndrome: a scientific and clinical update. <i>Leukemia and Lymphoma</i> , 1994 , 14, 375-8	1.9	16

24	Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. <i>Leukemia and Lymphoma</i> , 1994 , 14, 137-9	1.9	22
23	Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking. <i>Cancer</i> , 1994 , 73, 702-5	6.4	32
22	Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion. <i>American Journal of Hematology</i> , 1994 , 45, 187-8	7.1	40
21	Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. <i>American Journal of Hematology</i> , 1994 , 46, 325-8	7.1	22
20	Chronic natural killer cell lymphocytosis: a descriptive clinical study. <i>Blood</i> , 1994 , 84, 2721-5	2.2	26
19	Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?. <i>Blood</i> , 1994 , 84, 1620-1627	2.2	126
18	Chronic natural killer cell lymphocytosis: a descriptive clinical study. <i>Blood</i> , 1994 , 84, 2721-2725	2.2	2
17	Suramin toxicity and efficacy in agnogenic myeloid metaplasia. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 1520-2	9.7	13
16	The 5q- syndrome: a single-institution study of 43 consecutive patients. <i>Blood</i> , 1993 , 81, 1040-1045	2.2	79
15	The 5q- syndrome: a single-institution study of 43 consecutive patients. <i>Blood</i> , 1993 , 81, 1040-1045	2.2	
14	Secondary T-cell lymphoma in the setting of nodular lymphocyte predominance Hodgkin's disease. <i>American Journal of Hematology</i> , 1992 , 40, 232-3	7.1	9
13	Demonstration of clonality, by X-linked DNA analysis, in chronic natural killer cell lymphocytosis and successful therapy with oral cyclophosphamide. <i>Leukemia</i> , 1992 , 6, 477-80	10.7	18
12	Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 1990 , 8, 1959-65	2.2	23
11	Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. <i>Blood</i> , 1990 , 75, 1770-1773	2.2	107
10	Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. <i>Blood</i> , 1990 , 75, 1770-3	2.2	13
9	Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. <i>Blood</i> , 1990 , 75, 1770-1773	2.2	
8	Adult-onset cyclic bicytopenia: a case report and review of treatment of cyclic hematopoiesis. <i>American Journal of Hematology</i> , 1989 , 30, 181-5	7.1	12
7	Correlation of clinical outcome with the degree of surface immunoglobulin (sIg) expression in B-cell chronic lymphocytic leukemia. <i>American Journal of Clinical Pathology</i> , 1989 , 92, 82-5	1.9	15

6 Myeloproliferative Neoplasms: Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis147-156

5 Myeloproliferative Neoplasms47-61

4 Concurrent inflammatory bowel disease and myelodysplastic syndromes. *Inflammatory Bowel Diseases*,5, 98-103 4.5 10

3 Myeloproliferative neoplasms141-154

2 A Man with Progressive Effort Intolerance and Splenomegaly393-399

1 Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. *British Journal of Haematology*, 4.5 2